Antimicrobial Susceptibilities and Serogroups of Clinical Strains of Clostridium difficile Isolated in France in 1991 and 1997
- 1 November 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (11) , 2607-2611
- https://doi.org/10.1128/aac.43.11.2607
Abstract
Glycopeptides (vancomycin and teicoplanin) and metronidazole are the drugs of choice for the treatment of Clostridium difficile infections, but trends in susceptibility patterns have not been assessed in the past few years. The objective was to study the MICs of glycopeptides and metronidazole for unrelated C. difficile strains isolated in 1991 (n = 100) and in 1997 (n = 98) by the agar macrodilution, the E-test, and the disk diffusion methods. Strain susceptibilities to erythromycin, clindamycin, tetracycline, rifampin, and chloramphenicol were also determined by the ATB ANA gallery (bioMérieux, La Balme-les-Grottes, France). The MICs at which 50% of isolates are inhibited (MIC50s) and MIC90s of glycopeptides and metronidazole remained stable between 1991 and 1997. All the strains were inhibited by concentrations that did not exceed 2 μg/ml for vancomycin and 1 μg/ml for teicoplanin. Comparison of MICs determined by the agar dilution method recommended by the National Committee for Clinical Laboratory Standards and the E test showed correlations (±2 dilutions) of 86.6, 95.9, and 99% for metronidazole, vancomycin, and teicoplanin, respectively. The E test always underestimated the MICs. Strains with decreased susceptibility to metronidazole (MICs, ≥8 μg/ml) were isolated from six patients (n = 4 in 1991 and n = 2 in 1997). These strains were also detected by the disk diffusion method (zone inhibition diameter, ≤21 mm); they belonged to nontoxigenic serogroup D (n = 5) and toxigenic serogroup H (n = 1). Decreased susceptibility to erythromycin (MICs, ≥1 μg/ml), clindamycin (MICs, ≥2 μg/ml), tetracycline (MICs, ≥8 μg/ml), rifampin (MICs, ≥4 μg/ml), and chloramphenicol (MICs, ≥16 μg/ml) was observed in 64.2, 80.3, 23.7, 22.7, and 14.6% of strains, respectively. Strains isolated in 1997 were more susceptible than those isolated in 1991, and this trend was correlated to a major change in serogroup distribution. Periodic studies are needed in order to detect changes in serogroups and the emergence of strains with decreased susceptibility to therapeutic drugs.Keywords
This publication has 40 references indexed in Scilit:
- In Vitro Activity of Quinolones and Other Antimicrobial Agents Against Anaerobic BacteriaClinical Infectious Diseases, 1996
- Comparison of Vancomycin, Teicoplanin, Metronidazole, and Fusidic Acid for the Treatment of Clostridium difficile--Associated DiarrheaClinical Infectious Diseases, 1996
- Comparison of the E test and a reference agar dilution method for susceptibility testing of anaerobic bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Nosocomial Acquisition ofClostridium difficileInfectionNew England Journal of Medicine, 1989
- Correlation between serogroup and susceptibility to chloramphenicol, clindamycin, erythromycin, rifampicin and tetracycline among 308 isolates of Clostridium difficileJournal of Antimicrobial Chemotherapy, 1988
- Antimicrobial susceptibility of Clostridium difficile determined by disc diffusion and breakpoint methodsJournal of Antimicrobial Chemotherapy, 1988
- Epidemiology and prevention ofClostridium difficile infections in a leukemia unitEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenemJournal of Antimicrobial Chemotherapy, 1985
- This letter has been shown to Dr Gruer whose reply followsJournal of Antimicrobial Chemotherapy, 1985
- Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing ClostridiaNew England Journal of Medicine, 1978